{
    "organizations": [],
    "uuid": "3979d382def3a49c31cbb36d063c44f1460efe55",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cymabay-initiates-phase-2b-study-o/brief-cymabay-initiates-phase-2b-study-of-seladelpar-in-patients-with-non-alcoholic-steatohepatitis-idUSFWN1SF0M6",
    "ord_in_thread": 0,
    "title": "BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - CymaBay Therapeutics Inc:\n* CYMABAY THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS\n* CYMABAY THERAPEUTICS - IT BEGAN SCREENING OF PATIENTS FOR PHASE 2B PROOF OF CONCEPT STUDY OF SELADELPAR FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-08T20:15:00.000+03:00",
    "crawled": "2018-05-09T12:31:36.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "cymabay",
        "therapeutic",
        "inc",
        "cymabay",
        "therapeutic",
        "announces",
        "initiation",
        "phase",
        "2b",
        "study",
        "seladelpar",
        "patient",
        "steatohepatitis",
        "cymabay",
        "therapeutic",
        "began",
        "screening",
        "patient",
        "phase",
        "2b",
        "proof",
        "concept",
        "study",
        "seladelpar",
        "treatment",
        "steatohepatitis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}